Astrocytoma, IDH-Mutant, Grade 3

general

IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)

37

Centers

47

Active Trials

$3.3B

Cancer Funding

Specific Cancer Types(1)

NameCenters
Recurrent Astrocytoma, IDH-Mutant, Grade 418

Top Centers for Astrocytoma, IDH-Mutant, Grade 3(37)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
71.8
2
NCI Comprehensive
High-Volume Research Center
71.8
3
High-Volume Research Center
71.8
4
NCI Comprehensive
Active Research Program
49.3
5
NCI Comprehensive
Active Research Program
49.3
6
NCI Comprehensive
Active Research Program
49.3
7
NCI Comprehensive
Active Research Program
49.3
8
NCI Comprehensive
Active Research Program
49.3
9
NCI Comprehensive
Active Research Program
49.3
10
NCI Comprehensive
Active Research Program
49.3
11
NCI Comprehensive
Active Research Program
49.3
12
NCI Comprehensive
Active Research Program
49.3
13
NCI Comprehensive
Active Research Program
49.3
14
NCI Comprehensive
Active Research Program
49.3
15
NCI Comprehensive
Active Research Program
49.3
16
NCI Comprehensive
Active Research Program
49.3
17
NCI Comprehensive
Active Research Program
49.3
18
NCI Clinical
Active Research Program
49.3
19
NCI Comprehensive
Active Research Program
49.3
20
Active Research Program
49.3
21
Active Research Program
49.3
22
NCI Comprehensive
Active Research Program
49.3
23
NCI Comprehensive
Active Research Program
49.3
24
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
49.3
25
Active Research Program
49.3
26
Active Research Program
49.3
27
NCI Comprehensive
28
NCI Comprehensive
29
NCI Comprehensive
30
31
32
NCI Comprehensive
33
NCI Comprehensive
34
35
NCI Comprehensive
36
37

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →